SAN DIEGO, Feb 02, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the underwriters have exercised an
over-allotment option to purchase an additional 885,016 shares of its common
stock in connection with its follow-on stock offering that priced on
January 26, 2006. Inclu...
SAN DIEGO, March 2 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it will present at the Cowen & Co. 26th
Annual Health Care Conference on Tuesday, March 7, 2006, at 11:20 a.m. Eastern
Time (8:20 a.m. Pacific Time) at the Boston Marriott Copley Place, Boston,
Massachusetts. Robert E. Hoffma...
SAN DIEGO, Feb 22, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today reported financial results for the fourth quarter and
full year ended December 31, 2005.
Total revenues in the fourth quarter of 2005 were $5.9 million, compared
to $2.1 million in the fourth quarter of 2004. T...
SAN DIEGO, Feb. 16 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced it will report fourth quarter and full year
2005 financial results after the NASDAQ National Market closes on Wednesday,
February 22, 2006. That same afternoon Jack Lief, Arena's President and Chief
Executive Officer, and Robert E. Ho...
SAN DIEGO, Feb. 8 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it will present at the BIO CEO & Investor
Conference on Tuesday, February 14, 2006, at 2:30 p.m. Eastern Time
(11:30 a.m. Pacific Time) at the Waldorf Astoria, New York, New York. Louis
J. Scotti, Arena's Vice President, Marke...
SAN DIEGO, Feb 07, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that Ortho-McNeil, Inc., a Johnson & Johnson
company, initiated a Phase 1 clinical trial of APD668, a novel orally
administered drug candidate discovered by Arena for the treatment of Type 2
diabetes. The ...
SAN DIEGO, Feb. 2 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it will present at the Merrill Lynch
Global Pharmaceutical, Biotechnology & Medical Device Conference on Thursday,
February 9, 2006, at 4:00 p.m. Eastern Time (1:00 p.m. Pacific Time) at the
Grand Hyatt Hotel, New York, New Yor...
SAN DIEGO, Jan. 27 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today the pricing of its public offering of
9,752,508 shares of its common stock at a public offering price of $16.90 per
share. All of the shares are being offered by the company. The underwriters
have a 30-day option to purchase up to 1,...
SAN DIEGO, Jan. 17 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that it plans to publicly offer 8,500,000
shares of its common stock pursuant to an effective registration statement
previously filed with the Securities and Exchange Commission. In connection
with this offering, Arena plans to grant ...
SAN DIEGO, Jan 05, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it will present at the JPMorgan 24th
Annual Healthcare Conference on Thursday, January 12, 2006, at 11:30 a.m.
Pacific Time (2:30 p.m. Eastern Time) at the Westin St. Francis Hotel in San
Francisco, Califo...
SAN DIEGO, Jan. 3 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today the appointment of Robert E. Hoffman, C.P.A.,
as Chief Financial Officer. Mr. Hoffman has been with Arena since its
founding in 1997, and will continue to head Arena's financial group as the
company's principle financial and accounting...
SAN DIEGO, Dec. 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it was granted patent number 1558582,
entitled "Diaryl and Arylheteroaryl Urea Derivatives as Modulators of the
5-HT2A Serotonin Receptor Useful for the Prophylaxis and Treatment of
Disorders Related Thereto," by the European Pate...
SAN DIEGO, Dec. 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it is advancing APD791 into preclinical
development from its cardiovascular research program, and expects to initiate
clinical development in approximately one year. APD791 is a selective inverse
agonist of the 5-HT2A serotonin r...
SAN DIEGO, Dec. 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today positive top-line results from its Phase 2b
clinical trial of APD356, Arena's orally administered, internally discovered
drug candidate for the treatment of obesity. Over the 12 week treatment
period, there was a highly statistically ...
SAN DIEGO, Dec. 12 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that their lead compound for the treatment of
obesity, APD356, won San Diego based CONNECT's Most Innovative New Product
("MIP") Award in the Biotechnology Research and Development category. APD356
is a selective agonist of 5-HT2C ser...
SAN DIEGO, Nov 02, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it will present at the Rodman & Renshaw
Techvest 7th Annual Healthcare Conference on Tuesday, November 8, 2005, at
10:30 a.m. Eastern Time (7:30 a.m. Pacific Time) at the New York Palace Hotel
in New Y...
SAN DIEGO, Nov 02, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it will present at the CIBC World Markets
16th Annual Healthcare Conference on Tuesday, November 8, 2005, at 3:30 p.m.
Eastern Time (12:30 p.m. Pacific Time) at the Waldorf-Astoria in New York
City. Jack ...
SAN DIEGO, Oct. 18 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that data from its positive Phase 2a clinical
trial studying APD356 in 352 obese patients was the subject of a presentation
by Steven Smith, M.D., Principal Investigator and Associate Professor of the
Pennington Biomedical Research Cen...
SAN DIEGO, Oct. 17 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today reported financial results for the third quarter and nine
months ended September 30, 2005.
Total revenues in the third quarter of 2005 were $7.4 million, compared to
$4.4 million in the third quarter of 2004. Total revenues in the ni...
SAN DIEGO, Oct. 12 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it will present at the 2005 BIO
InvestorForum on Wednesday, October 19, 2005, at 10:20 a.m. Pacific Time (1:20
p.m. Eastern Time) at The Palace Hotel in San Francisco, California. Jack
Lief, Arena's President and Chief Executive ...
